JP2013538829A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538829A5
JP2013538829A5 JP2013530333A JP2013530333A JP2013538829A5 JP 2013538829 A5 JP2013538829 A5 JP 2013538829A5 JP 2013530333 A JP2013530333 A JP 2013530333A JP 2013530333 A JP2013530333 A JP 2013530333A JP 2013538829 A5 JP2013538829 A5 JP 2013538829A5
Authority
JP
Japan
Prior art keywords
agent
targeted delivery
conjugate
group
nanocarrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530333A
Other languages
English (en)
Japanese (ja)
Other versions
JP5927194B2 (ja
JP2013538829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/052856 external-priority patent/WO2012040524A1/en
Publication of JP2013538829A publication Critical patent/JP2013538829A/ja
Publication of JP2013538829A5 publication Critical patent/JP2013538829A5/ja
Application granted granted Critical
Publication of JP5927194B2 publication Critical patent/JP5927194B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530333A 2010-09-24 2011-09-23 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート Expired - Fee Related JP5927194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38620110P 2010-09-24 2010-09-24
US61/386,201 2010-09-24
PCT/US2011/052856 WO2012040524A1 (en) 2010-09-24 2011-09-23 Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015210354A Division JP2016026205A (ja) 2010-09-24 2015-10-27 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Publications (3)

Publication Number Publication Date
JP2013538829A JP2013538829A (ja) 2013-10-17
JP2013538829A5 true JP2013538829A5 (cg-RX-API-DMAC7.html) 2014-10-09
JP5927194B2 JP5927194B2 (ja) 2016-06-01

Family

ID=44774137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013530333A Expired - Fee Related JP5927194B2 (ja) 2010-09-24 2011-09-23 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
JP2015210354A Pending JP2016026205A (ja) 2010-09-24 2015-10-27 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015210354A Pending JP2016026205A (ja) 2010-09-24 2015-10-27 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Country Status (8)

Country Link
US (1) US20120082616A1 (cg-RX-API-DMAC7.html)
EP (1) EP2618846A1 (cg-RX-API-DMAC7.html)
JP (2) JP5927194B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130136983A (cg-RX-API-DMAC7.html)
CN (1) CN103269722A (cg-RX-API-DMAC7.html)
CA (1) CA2811601A1 (cg-RX-API-DMAC7.html)
IL (1) IL225414A0 (cg-RX-API-DMAC7.html)
WO (1) WO2012040524A1 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
KR101525132B1 (ko) * 2008-10-08 2015-06-02 포항공과대학교 산학협력단 X 선용 조영제 캡슐 및 이의 제조방법
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN103476798B (zh) * 2011-04-15 2017-04-05 首尔大学校产学协力团 在粘合物质和可铁宁的粘合体上结合有抗‑可铁宁抗体的复合体及其用途
JP2014528411A (ja) * 2011-09-30 2014-10-27 マリンクロッド エルエルシー 相補的オリゴヌクレオチドリンカーを用いる標的化ナノ粒子の遠隔アセンブリ
RU2493848C1 (ru) * 2012-06-14 2013-09-27 Геннадий Петрович Власов Биодеградируемый полимерный носитель для доставки противоопухолевого лекарственного средства (варианты)
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015126502A2 (en) 2013-12-03 2015-08-27 Northwestern University Liposomal particles, methods of making same and uses thereof
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
JP6595232B2 (ja) 2015-07-02 2019-10-23 ソニー・オリンパスメディカルソリューションズ株式会社 内視鏡用撮像装置、内視鏡装置、及び内視鏡用ケーブル
KR101704379B1 (ko) * 2015-10-27 2017-02-08 (주)알테오젠 항체-약물 접합체 및 그 제조방법
AU2016392719A1 (en) * 2016-02-10 2018-08-02 Pfizer Inc. Therapeutic nanoparticles having EGFR ligands and methods of making and using same
KR101856838B1 (ko) * 2016-02-17 2018-06-19 이희정 베타-아밀로이드 올리고머에 대한 압타머 및 이의 용도
CA3023451A1 (en) * 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
KR102015524B1 (ko) * 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
CA3069125A1 (en) * 2017-07-07 2019-01-10 Drexel University Voltage-activated therapeutic, diagnostic, and/or theranostic constructs
CN107998080A (zh) * 2017-11-21 2018-05-08 东南大学 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
JP7424976B2 (ja) 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルCoAカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
US11007211B2 (en) 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
CN110573144B (zh) 2018-01-22 2021-02-26 北京茵诺医药科技有限公司 用于靶向活化cd44分子的硅质体纳米载体递送系统、其制备方法和用途
KR101977532B1 (ko) * 2018-03-09 2019-05-10 연세대학교 원주산학협력단 약물, 양자점 및 표적화제를 포함하는 나노 마이셀 및 이의 용도
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (fr) 2018-09-02 2021-07-14 Modernatx Inc Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
JP2022500436A (ja) 2018-09-13 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド
US12644102B2 (en) 2018-09-13 2026-06-02 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex E1-α, E1-β, and E2 subunits for the treatment of maple syrup urine disease
MA53615A (fr) 2018-09-14 2021-07-21 Modernatx Inc Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
WO2020069169A1 (en) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
CN113906293A (zh) * 2019-05-31 2022-01-07 株式会社新日本科学 使用色谱质谱分析装置的质谱分析方法
CN110787149A (zh) * 2019-11-12 2020-02-14 深圳碳十四科技创新有限公司 双壳层纳米粒子及其制备方法
AU2021285812A1 (en) 2020-06-01 2023-01-05 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
IL300676A (en) * 2020-08-20 2023-04-01 Bionanosim Bns Ltd A lipid system for the administration of OCA
CA3199784A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023215616A2 (en) * 2022-05-05 2023-11-09 Aion Healthspan, Inc. Nanomaterial-stem cell compositions and methods of use
EP4562163A1 (en) 2022-07-26 2025-06-04 ModernaTX, Inc. Engineered polynucleotides for temporal control of expression
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024182301A2 (en) 2023-02-27 2024-09-06 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
EP4704816A1 (en) 2023-05-03 2026-03-11 ModernaTX, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
DE10049074A1 (de) 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
US20100015041A1 (en) 2005-01-18 2010-01-21 Caltagirone Gaetano T Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof

Similar Documents

Publication Publication Date Title
He et al. Aptamer-based targeted drug delivery systems: current potential and challenges
US8889657B2 (en) Nanoparticle PEG modification with H-phosphonates
JP5927194B2 (ja) 治療ナノキャリアおよび/または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
Allen et al. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer
Mussi et al. Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics
JP2014527071A5 (cg-RX-API-DMAC7.html)
JP2014528411A5 (cg-RX-API-DMAC7.html)
JP2015502946A5 (cg-RX-API-DMAC7.html)
Hani et al. A comprehensive review of current perspectives on novel drug Delivery systems and approaches for lung cancer management
US20140234217A1 (en) Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers
Zanganeh et al. Immunoengineering in glioblastoma imaging and therapy
Zoulikha et al. Targeted Drug Delivery for Chronic Lymphocytic Leukemia: Zoulikha and He
Yang et al. Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging
WO2016134066A1 (en) Modified docetaxel liposome formulations and uses thereof
TWI760319B (zh) 乳癌治療
Yu et al. Surface modification of nanocarriers for cancer therapy
Stanczyk et al. Dendrimers in therapy for breast and colorectal cancer
JP2014525459A5 (cg-RX-API-DMAC7.html)
Zhu et al. Current progresses of functional nanomaterials for imaging diagnosis and treatment of melanoma
CA2845851A1 (en) Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions
Kim et al. Image-guided nanoparticle-based siRNA delivery for cancer therapy
Svenson Preclinical to clinical development of nanomedicines
Torchilin Polymeric micelles for therapeutic applications in medicine
Javius-Jones Targeted Dendritic-lipid Nanoparticles for Combination Cancer Therapy
Riviere Investigation of the Enhancement of Drug Synergy by Co-Delivery in Targeted Liposomes